Abstract:Objective: To clarify the molecular basis of patients with Bartter syndrome type I and explore the therapeutic effect of trafficking-defective variations by chemical chaperone 4-Phenylbutyric acid(4-PBA). Methods: The clinical characteristics, laboratory findings and genetic data of 3 patients diagnosed with Bartter syndrome type I who were admitted to Department of Nephrology, Children's Hospital of Nanjing Medical University from 2017 to 2018 were retrospectively analyzed. Wild type and variant SLC12A1 gene constructs were transiently overexpressed in HEK293 cells. Western blotting was used to detect the expression levels of Na+-K+-2Cl-cotransporter(NKCC2) protein. Immunofluorescent staining was applied to investigate the subcellular localization of NKCC2 protein. In addition, the effect of the chemical chaperone 4-PBA on the expression and localization of the SLC12A1 gene variants was investigated. Unpaired t test was used for statistical analysis of 4-PBA treatment. Results: All the 3 patients (2 males and 1 female), aged 3.0, 4.0 and 1.2 years, respectively. All patients had antenatal onset with polyhydramnios and were born prematurely. After birth, all patients presented with hypochlorine alkalosis accompanied by hypokalemia and hyponatremia. Sequencing analysis revealed that the 3 patients were homozygotes or compound heterozygotes for variants in the SLC12A1 gene. In HEK293 cells, the surface expression of NKCC2 in 3 variants (p.L463S, p.L479V, p.507-510del) are all lower than in wild type (0.718±0.039, 0.287±0.081, 0.025±0.156 vs. 1.001±0.028, t=5.92, 8.35, 30.49, all P<0.01). Moreover, the total protein expression of p.L479V and p.507-510del group were all lower than that in wild type group (0.630±0.032, 0.043±0.003 vs. 1.000±0.111, t=3.21, 8.65, all P<0.05). 4-PBA treatment increased the mature protein expression level of the p.L463S and p. L479V group in 4-PBA treatment group are all higher than the untreated group (0.459±0.018 vs. 1.123±0.024, 0.053±0.012 vs. 1.256±0.037, t=2.75, 18.35, all P<0.05). Cytoplasmic retention of the L479V and 507-510del variants were observed by immunofluorescent staining. 4-PBA treatment could rescue a number of NKCC2 L479V variants to the membrane. Conclusions: The 3 SLC12A1 variants cause expression or subcellular localization defects of the protein. The findings that plasma membrane expression and activity can be rescued by 4PBA might help to develop novel therapeutic strategy for Bartter syndrome type Ⅰ.

Novel SLC12A1 mutations cause Bartter syndrome in two patients with different prognoses

Digenetic Inheritance of SLC12A3 and CLCNKB Genes in a Chinese Girl with Gitelman Syndrome

A Chinese Girl with Bartter Syndrome Type III Due to a Novel Mutation And/or Single Nucleotide Polymorphisms (snps) in CLCNKB Gene

Genetic heterogeneity in patients with Bartter syndrome type 1.

[Functional Characterization of SLC12A1 Gene Variants in 3 Patients with Bartter Syndrome Type Ⅰ].

Novel Compound Heterozygousclcnkbgene Mutations (c.1755a>g/c.848_850deltct) Cause Classic Bartter Syndrome

A Novel Splicing Mutation in Clcnkb in A Chinese Patient with Bartter Syndrome Type Iii

[Advance in Genetic Research on Gitelman Syndrome].

Simultaneous Homozygous Mutations in SLC12A3 and CLCNKB in an Inbred Chinese Pedigree

Clinical Features and Unusual Heterozygous Mutations in Patients with Renal Hypokalemia

Study on CLCNKB gene mutation in a late-onset Chinese patient with classic Bartter syndrome

Splicing Characterization of CLCNKB Variants in Four Patients with Type III Bartter Syndrome

A Novel CLCNKB Variant in a Chinese Family with Classic Bartter Syndrome and Prenatal Genetic Diagnosis.

Bartter Syndrome Type III with Only a Synonymous Mutation of the CLCNKB Gene

A Novel Compound Heterozygous Variant of the SLC12A3 Gene in Gitelman Syndrome Pedigree

ClC-Kb pore mutation disrupts glycosylation and triggers distal tubular remodeling

A New Case Report of a CLCNKB Complex Heterozygous Mutation in Adult-Onset Type III Bartter Syndrome

Novel Heterozygous GATA3 and SLC34A3 Variants in a 6‐year‐old Boy with Barakat Syndrome and Hypercalciuria

Digenic Mutations Involving Both the BSND and GJB2 Genes Detected in Bartter Syndrome Type IV.

A Novel Mutation Associated with Type III Bartter Syndrome: A Report of Five Cases.

The Bartter-Gitelman Spectrum: 50-Year Follow-up With Revision of Diagnosis After Whole-Genome Sequencing